Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.51 million
Profitability
Miscellaneous
Employees360
Next Earnings Date2/26/2019 (Confirmed)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $0.11. The biopharmaceutical company earned $22.76 million during the quarter, compared to the consensus estimate of $30.11 million. Clovis Oncology had a negative return on equity of 108.92% and a negative net margin of 390.65%. The firm's revenue was up 35.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.24) EPS. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
How can I listen to Clovis Oncology's earnings call?
Clovis Oncology will be holding an earnings conference call on Tuesday, February 26th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for CLVS?
13 brokerages have issued twelve-month price targets for Clovis Oncology's shares. Their forecasts range from $16.00 to $110.00. On average, they anticipate Clovis Oncology's share price to reach $53.8520 in the next year. This suggests a possible upside of 112.7% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
Has Clovis Oncology been receiving favorable news coverage?
News headlines about CLVS stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Clovis Oncology earned a news impact score of 1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include United Therapeutics (UTHR), Alkermes (ALKS), Patheon (PTHN), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO) and Emergent Biosolutions (EBS).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (5.22%), Samlyn Capital LLC (1.91%), Geode Capital Management LLC (1.09%), Elk Creek Partners LLC (0.72%), KBC Group NV (0.60%) and Dimensional Fund Advisors LP (0.60%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which major investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Amundi Pioneer Asset Management Inc., Hudson Bay Capital Management LP, Bank of Montreal Can, MetLife Investment Advisors LLC, Principal Financial Group Inc., Stifel Financial Corp and California Public Employees Retirement System. Company insiders that have sold Clovis Oncology company stock in the last year include Lindsey Rolfe and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which major investors are buying Clovis Oncology stock?
CLVS stock was purchased by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Orbimed Advisors LLC, Elk Creek Partners LLC, Dimensional Fund Advisors LP, Sofinnova Investments Inc., Candriam Luxembourg S.C.A., KBC Group NV and Squarepoint Ops LLC. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $25.32.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $1.33 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
